The global Solid Tumor Non-Conventional Testing market size was valued at US$ million in 2024 and is forecast to a readjusted size of USD million by 2031 with a CAGR of %during review period.
Solid tumors are abnormal masses of tissue that do not generally contain cysts or liquid regions. Solid tumors can be benign (not cancerous) or malignant (cancerous). Different types of solid tumors are named for the type of cells that form them. Sarcomas, carcinomas, and lymphomas are examples of solid tumors. A solid tumor is one of the most prevalent causes of death, despite enormous efforts to explore solid tumor biology and developed test for the diagnosis of solid tumors. This report focus on Non-Conventional Testing market.
This report is a detailed and comprehensive analysis for global Solid Tumor Non-Conventional Testing market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Solid Tumor Non-Conventional Testing market size and forecasts, in consumption value ($ Million), 2020-2031
Global Solid Tumor Non-Conventional Testing market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Solid Tumor Non-Conventional Testing market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Solid Tumor Non-Conventional Testing market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Solid Tumor Non-Conventional Testing
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Solid Tumor Non-Conventional Testing market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Abbott Laboratories, Agilent Technologies, Avant Diagnostics, Inc., Advanced Cell Diagnostics, Inc., Agena Bioscience, Inc., ARUP Laboratories, Bio-Rad Laboratories, Inc., Biocare Medical, LLC., Caris Life Sciences., F. Hoffmann-La Roche Ltd, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Solid Tumor Non-Conventional Testing market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Fluorescence in-situ Hybridization (FISH)
Immunohistochemistry (IHC)
Polymerase Chain Reaction (PCR)
Next-generation Sequencing (NGS)
Others
Market segment by Application
Hospitals
Pharmaceutical and Biotechnology Companies
Others
Market segment by players, this report covers
Abbott Laboratories
Agilent Technologies
Avant Diagnostics, Inc.
Advanced Cell Diagnostics, Inc.
Agena Bioscience, Inc.
ARUP Laboratories
Bio-Rad Laboratories, Inc.
Biocare Medical, LLC.
Caris Life Sciences.
F. Hoffmann-La Roche Ltd
Foundation Medicine
Genomic Testing Cooperative
Guardant Health
HTG Molecular Diagnostics, Inc.
Illumina, Inc.
Invitae Corporation
Invivoscribe, Inc.
Johnson & Johnson
Laboratory Corporation of America Holdings
MedGenome Labs Private Ltd.
Myraid Genetics, Inc.
Nanjing Geneseeq
NanoString
NeoGenomics Laboratories
Opko Health, Inc.
QIAGEN
Quest Diagnostics Incorporated.
Thermo Fisher Scientific, Inc.
VYANTbio.
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Solid Tumor Non-Conventional Testing product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Solid Tumor Non-Conventional Testing, with revenue, gross margin, and global market share of Solid Tumor Non-Conventional Testing from 2020 to 2025.
Chapter 3, the Solid Tumor Non-Conventional Testing competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Solid Tumor Non-Conventional Testing market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Solid Tumor Non-Conventional Testing.
Chapter 13, to describe Solid Tumor Non-Conventional Testing research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 Market Overview
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Solid Tumor Non-Conventional Testing by Type
1.3.1 Overview: Global Solid Tumor Non-Conventional Testing Market Size by Type: 2020 Versus 2024 Versus 2031
1.3.2 Global Solid Tumor Non-Conventional Testing Consumption Value Market Share by Type in 2024
1.3.3 Fluorescence in-situ Hybridization (FISH)
1.3.4 Immunohistochemistry (IHC)
1.3.5 Polymerase Chain Reaction (PCR)
1.3.6 Next-generation Sequencing (NGS)
1.3.7 Others
1.4 Global Solid Tumor Non-Conventional Testing Market by Application
1.4.1 Overview: Global Solid Tumor Non-Conventional Testing Market Size by Application: 2020 Versus 2024 Versus 2031
1.4.2 Hospitals
1.4.3 Pharmaceutical and Biotechnology Companies
1.4.4 Others
1.5 Global Solid Tumor Non-Conventional Testing Market Size & Forecast
1.6 Global Solid Tumor Non-Conventional Testing Market Size and Forecast by Region
1.6.1 Global Solid Tumor Non-Conventional Testing Market Size by Region: 2020 VS 2024 VS 2031
1.6.2 Global Solid Tumor Non-Conventional Testing Market Size by Region, (2020-2031)
1.6.3 North America Solid Tumor Non-Conventional Testing Market Size and Prospect (2020-2031)
1.6.4 Europe Solid Tumor Non-Conventional Testing Market Size and Prospect (2020-2031)
1.6.5 Asia-Pacific Solid Tumor Non-Conventional Testing Market Size and Prospect (2020-2031)
1.6.6 South America Solid Tumor Non-Conventional Testing Market Size and Prospect (2020-2031)
1.6.7 Middle East & Africa Solid Tumor Non-Conventional Testing Market Size and Prospect (2020-2031)
2 Company Profiles
2.1 Abbott Laboratories
2.1.1 Abbott Laboratories Details
2.1.2 Abbott Laboratories Major Business
2.1.3 Abbott Laboratories Solid Tumor Non-Conventional Testing Product and Solutions
2.1.4 Abbott Laboratories Solid Tumor Non-Conventional Testing Revenue, Gross Margin and Market Share (2020-2025)
2.1.5 Abbott Laboratories Recent Developments and Future Plans
2.2 Agilent Technologies
2.2.1 Agilent Technologies Details
2.2.2 Agilent Technologies Major Business
2.2.3 Agilent Technologies Solid Tumor Non-Conventional Testing Product and Solutions
2.2.4 Agilent Technologies Solid Tumor Non-Conventional Testing Revenue, Gross Margin and Market Share (2020-2025)
2.2.5 Agilent Technologies Recent Developments and Future Plans
2.3 Avant Diagnostics, Inc.
2.3.1 Avant Diagnostics, Inc. Details
2.3.2 Avant Diagnostics, Inc. Major Business
2.3.3 Avant Diagnostics, Inc. Solid Tumor Non-Conventional Testing Product and Solutions
2.3.4 Avant Diagnostics, Inc. Solid Tumor Non-Conventional Testing Revenue, Gross Margin and Market Share (2020-2025)
2.3.5 Avant Diagnostics, Inc. Recent Developments and Future Plans
2.4 Advanced Cell Diagnostics, Inc.
2.4.1 Advanced Cell Diagnostics, Inc. Details
2.4.2 Advanced Cell Diagnostics, Inc. Major Business
2.4.3 Advanced Cell Diagnostics, Inc. Solid Tumor Non-Conventional Testing Product and Solutions
2.4.4 Advanced Cell Diagnostics, Inc. Solid Tumor Non-Conventional Testing Revenue, Gross Margin and Market Share (2020-2025)
2.4.5 Advanced Cell Diagnostics, Inc. Recent Developments and Future Plans
2.5 Agena Bioscience, Inc.
2.5.1 Agena Bioscience, Inc. Details
2.5.2 Agena Bioscience, Inc. Major Business
2.5.3 Agena Bioscience, Inc. Solid Tumor Non-Conventional Testing Product and Solutions
2.5.4 Agena Bioscience, Inc. Solid Tumor Non-Conventional Testing Revenue, Gross Margin and Market Share (2020-2025)
2.5.5 Agena Bioscience, Inc. Recent Developments and Future Plans
2.6 ARUP Laboratories
2.6.1 ARUP Laboratories Details
2.6.2 ARUP Laboratories Major Business
2.6.3 ARUP Laboratories Solid Tumor Non-Conventional Testing Product and Solutions
2.6.4 ARUP Laboratories Solid Tumor Non-Conventional Testing Revenue, Gross Margin and Market Share (2020-2025)
2.6.5 ARUP Laboratories Recent Developments and Future Plans
2.7 Bio-Rad Laboratories, Inc.
2.7.1 Bio-Rad Laboratories, Inc. Details
2.7.2 Bio-Rad Laboratories, Inc. Major Business
2.7.3 Bio-Rad Laboratories, Inc. Solid Tumor Non-Conventional Testing Product and Solutions
2.7.4 Bio-Rad Laboratories, Inc. Solid Tumor Non-Conventional Testing Revenue, Gross Margin and Market Share (2020-2025)
2.7.5 Bio-Rad Laboratories, Inc. Recent Developments and Future Plans
2.8 Biocare Medical, LLC.
2.8.1 Biocare Medical, LLC. Details
2.8.2 Biocare Medical, LLC. Major Business
2.8.3 Biocare Medical, LLC. Solid Tumor Non-Conventional Testing Product and Solutions
2.8.4 Biocare Medical, LLC. Solid Tumor Non-Conventional Testing Revenue, Gross Margin and Market Share (2020-2025)
2.8.5 Biocare Medical, LLC. Recent Developments and Future Plans
2.9 Caris Life Sciences.
2.9.1 Caris Life Sciences. Details
2.9.2 Caris Life Sciences. Major Business
2.9.3 Caris Life Sciences. Solid Tumor Non-Conventional Testing Product and Solutions
2.9.4 Caris Life Sciences. Solid Tumor Non-Conventional Testing Revenue, Gross Margin and Market Share (2020-2025)
2.9.5 Caris Life Sciences. Recent Developments and Future Plans
2.10 F. Hoffmann-La Roche Ltd
2.10.1 F. Hoffmann-La Roche Ltd Details
2.10.2 F. Hoffmann-La Roche Ltd Major Business
2.10.3 F. Hoffmann-La Roche Ltd Solid Tumor Non-Conventional Testing Product and Solutions
2.10.4 F. Hoffmann-La Roche Ltd Solid Tumor Non-Conventional Testing Revenue, Gross Margin and Market Share (2020-2025)
2.10.5 F. Hoffmann-La Roche Ltd Recent Developments and Future Plans
2.11 Foundation Medicine
2.11.1 Foundation Medicine Details
2.11.2 Foundation Medicine Major Business
2.11.3 Foundation Medicine Solid Tumor Non-Conventional Testing Product and Solutions
2.11.4 Foundation Medicine Solid Tumor Non-Conventional Testing Revenue, Gross Margin and Market Share (2020-2025)
2.11.5 Foundation Medicine Recent Developments and Future Plans
2.12 Genomic Testing Cooperative
2.12.1 Genomic Testing Cooperative Details
2.12.2 Genomic Testing Cooperative Major Business
2.12.3 Genomic Testing Cooperative Solid Tumor Non-Conventional Testing Product and Solutions
2.12.4 Genomic Testing Cooperative Solid Tumor Non-Conventional Testing Revenue, Gross Margin and Market Share (2020-2025)
2.12.5 Genomic Testing Cooperative Recent Developments and Future Plans
2.13 Guardant Health
2.13.1 Guardant Health Details
2.13.2 Guardant Health Major Business
2.13.3 Guardant Health Solid Tumor Non-Conventional Testing Product and Solutions
2.13.4 Guardant Health Solid Tumor Non-Conventional Testing Revenue, Gross Margin and Market Share (2020-2025)
2.13.5 Guardant Health Recent Developments and Future Plans
2.14 HTG Molecular Diagnostics, Inc.
2.14.1 HTG Molecular Diagnostics, Inc. Details
2.14.2 HTG Molecular Diagnostics, Inc. Major Business
2.14.3 HTG Molecular Diagnostics, Inc. Solid Tumor Non-Conventional Testing Product and Solutions
2.14.4 HTG Molecular Diagnostics, Inc. Solid Tumor Non-Conventional Testing Revenue, Gross Margin and Market Share (2020-2025)
2.14.5 HTG Molecular Diagnostics, Inc. Recent Developments and Future Plans
2.15 Illumina, Inc.
2.15.1 Illumina, Inc. Details
2.15.2 Illumina, Inc. Major Business
2.15.3 Illumina, Inc. Solid Tumor Non-Conventional Testing Product and Solutions
2.15.4 Illumina, Inc. Solid Tumor Non-Conventional Testing Revenue, Gross Margin and Market Share (2020-2025)
2.15.5 Illumina, Inc. Recent Developments and Future Plans
2.16 Invitae Corporation
2.16.1 Invitae Corporation Details
2.16.2 Invitae Corporation Major Business
2.16.3 Invitae Corporation Solid Tumor Non-Conventional Testing Product and Solutions
2.16.4 Invitae Corporation Solid Tumor Non-Conventional Testing Revenue, Gross Margin and Market Share (2020-2025)
2.16.5 Invitae Corporation Recent Developments and Future Plans
2.17 Invivoscribe, Inc.
2.17.1 Invivoscribe, Inc. Details
2.17.2 Invivoscribe, Inc. Major Business
2.17.3 Invivoscribe, Inc. Solid Tumor Non-Conventional Testing Product and Solutions
2.17.4 Invivoscribe, Inc. Solid Tumor Non-Conventional Testing Revenue, Gross Margin and Market Share (2020-2025)
2.17.5 Invivoscribe, Inc. Recent Developments and Future Plans
2.18 Johnson & Johnson
2.18.1 Johnson & Johnson Details
2.18.2 Johnson & Johnson Major Business
2.18.3 Johnson & Johnson Solid Tumor Non-Conventional Testing Product and Solutions
2.18.4 Johnson & Johnson Solid Tumor Non-Conventional Testing Revenue, Gross Margin and Market Share (2020-2025)
2.18.5 Johnson & Johnson Recent Developments and Future Plans
2.19 Laboratory Corporation of America Holdings
2.19.1 Laboratory Corporation of America Holdings Details
2.19.2 Laboratory Corporation of America Holdings Major Business
2.19.3 Laboratory Corporation of America Holdings Solid Tumor Non-Conventional Testing Product and Solutions
2.19.4 Laboratory Corporation of America Holdings Solid Tumor Non-Conventional Testing Revenue, Gross Margin and Market Share (2020-2025)
2.19.5 Laboratory Corporation of America Holdings Recent Developments and Future Plans
2.20 MedGenome Labs Private Ltd.
2.20.1 MedGenome Labs Private Ltd. Details
2.20.2 MedGenome Labs Private Ltd. Major Business
2.20.3 MedGenome Labs Private Ltd. Solid Tumor Non-Conventional Testing Product and Solutions
2.20.4 MedGenome Labs Private Ltd. Solid Tumor Non-Conventional Testing Revenue, Gross Margin and Market Share (2020-2025)
2.20.5 MedGenome Labs Private Ltd. Recent Developments and Future Plans
2.21 Myraid Genetics, Inc.
2.21.1 Myraid Genetics, Inc. Details
2.21.2 Myraid Genetics, Inc. Major Business
2.21.3 Myraid Genetics, Inc. Solid Tumor Non-Conventional Testing Product and Solutions
2.21.4 Myraid Genetics, Inc. Solid Tumor Non-Conventional Testing Revenue, Gross Margin and Market Share (2020-2025)
2.21.5 Myraid Genetics, Inc. Recent Developments and Future Plans
2.22 Nanjing Geneseeq
2.22.1 Nanjing Geneseeq Details
2.22.2 Nanjing Geneseeq Major Business
2.22.3 Nanjing Geneseeq Solid Tumor Non-Conventional Testing Product and Solutions
2.22.4 Nanjing Geneseeq Solid Tumor Non-Conventional Testing Revenue, Gross Margin and Market Share (2020-2025)
2.22.5 Nanjing Geneseeq Recent Developments and Future Plans
2.23 NanoString
2.23.1 NanoString Details
2.23.2 NanoString Major Business
2.23.3 NanoString Solid Tumor Non-Conventional Testing Product and Solutions
2.23.4 NanoString Solid Tumor Non-Conventional Testing Revenue, Gross Margin and Market Share (2020-2025)
2.23.5 NanoString Recent Developments and Future Plans
2.24 NeoGenomics Laboratories
2.24.1 NeoGenomics Laboratories Details
2.24.2 NeoGenomics Laboratories Major Business
2.24.3 NeoGenomics Laboratories Solid Tumor Non-Conventional Testing Product and Solutions
2.24.4 NeoGenomics Laboratories Solid Tumor Non-Conventional Testing Revenue, Gross Margin and Market Share (2020-2025)
2.24.5 NeoGenomics Laboratories Recent Developments and Future Plans
2.25 Opko Health, Inc.
2.25.1 Opko Health, Inc. Details
2.25.2 Opko Health, Inc. Major Business
2.25.3 Opko Health, Inc. Solid Tumor Non-Conventional Testing Product and Solutions
2.25.4 Opko Health, Inc. Solid Tumor Non-Conventional Testing Revenue, Gross Margin and Market Share (2020-2025)
2.25.5 Opko Health, Inc. Recent Developments and Future Plans
2.26 QIAGEN
2.26.1 QIAGEN Details
2.26.2 QIAGEN Major Business
2.26.3 QIAGEN Solid Tumor Non-Conventional Testing Product and Solutions
2.26.4 QIAGEN Solid Tumor Non-Conventional Testing Revenue, Gross Margin and Market Share (2020-2025)
2.26.5 QIAGEN Recent Developments and Future Plans
2.27 Quest Diagnostics Incorporated.
2.27.1 Quest Diagnostics Incorporated. Details
2.27.2 Quest Diagnostics Incorporated. Major Business
2.27.3 Quest Diagnostics Incorporated. Solid Tumor Non-Conventional Testing Product and Solutions
2.27.4 Quest Diagnostics Incorporated. Solid Tumor Non-Conventional Testing Revenue, Gross Margin and Market Share (2020-2025)
2.27.5 Quest Diagnostics Incorporated. Recent Developments and Future Plans
2.28 Thermo Fisher Scientific, Inc.
2.28.1 Thermo Fisher Scientific, Inc. Details
2.28.2 Thermo Fisher Scientific, Inc. Major Business
2.28.3 Thermo Fisher Scientific, Inc. Solid Tumor Non-Conventional Testing Product and Solutions
2.28.4 Thermo Fisher Scientific, Inc. Solid Tumor Non-Conventional Testing Revenue, Gross Margin and Market Share (2020-2025)
2.28.5 Thermo Fisher Scientific, Inc. Recent Developments and Future Plans
2.29 VYANTbio.
2.29.1 VYANTbio. Details
2.29.2 VYANTbio. Major Business
2.29.3 VYANTbio. Solid Tumor Non-Conventional Testing Product and Solutions
2.29.4 VYANTbio. Solid Tumor Non-Conventional Testing Revenue, Gross Margin and Market Share (2020-2025)
2.29.5 VYANTbio. Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Solid Tumor Non-Conventional Testing Revenue and Share by Players (2020-2025)
3.2 Market Share Analysis (2024)
3.2.1 Market Share of Solid Tumor Non-Conventional Testing by Company Revenue
3.2.2 Top 3 Solid Tumor Non-Conventional Testing Players Market Share in 2024
3.2.3 Top 6 Solid Tumor Non-Conventional Testing Players Market Share in 2024
3.3 Solid Tumor Non-Conventional Testing Market: Overall Company Footprint Analysis
3.3.1 Solid Tumor Non-Conventional Testing Market: Region Footprint
3.3.2 Solid Tumor Non-Conventional Testing Market: Company Product Type Footprint
3.3.3 Solid Tumor Non-Conventional Testing Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type
4.1 Global Solid Tumor Non-Conventional Testing Consumption Value and Market Share by Type (2020-2025)
4.2 Global Solid Tumor Non-Conventional Testing Market Forecast by Type (2026-2031)
5 Market Size Segment by Application
5.1 Global Solid Tumor Non-Conventional Testing Consumption Value Market Share by Application (2020-2025)
5.2 Global Solid Tumor Non-Conventional Testing Market Forecast by Application (2026-2031)
6 North America
6.1 North America Solid Tumor Non-Conventional Testing Consumption Value by Type (2020-2031)
6.2 North America Solid Tumor Non-Conventional Testing Market Size by Application (2020-2031)
6.3 North America Solid Tumor Non-Conventional Testing Market Size by Country
6.3.1 North America Solid Tumor Non-Conventional Testing Consumption Value by Country (2020-2031)
6.3.2 United States Solid Tumor Non-Conventional Testing Market Size and Forecast (2020-2031)
6.3.3 Canada Solid Tumor Non-Conventional Testing Market Size and Forecast (2020-2031)
6.3.4 Mexico Solid Tumor Non-Conventional Testing Market Size and Forecast (2020-2031)
7 Europe
7.1 Europe Solid Tumor Non-Conventional Testing Consumption Value by Type (2020-2031)
7.2 Europe Solid Tumor Non-Conventional Testing Consumption Value by Application (2020-2031)
7.3 Europe Solid Tumor Non-Conventional Testing Market Size by Country
7.3.1 Europe Solid Tumor Non-Conventional Testing Consumption Value by Country (2020-2031)
7.3.2 Germany Solid Tumor Non-Conventional Testing Market Size and Forecast (2020-2031)
7.3.3 France Solid Tumor Non-Conventional Testing Market Size and Forecast (2020-2031)
7.3.4 United Kingdom Solid Tumor Non-Conventional Testing Market Size and Forecast (2020-2031)
7.3.5 Russia Solid Tumor Non-Conventional Testing Market Size and Forecast (2020-2031)
7.3.6 Italy Solid Tumor Non-Conventional Testing Market Size and Forecast (2020-2031)
8 Asia-Pacific
8.1 Asia-Pacific Solid Tumor Non-Conventional Testing Consumption Value by Type (2020-2031)
8.2 Asia-Pacific Solid Tumor Non-Conventional Testing Consumption Value by Application (2020-2031)
8.3 Asia-Pacific Solid Tumor Non-Conventional Testing Market Size by Region
8.3.1 Asia-Pacific Solid Tumor Non-Conventional Testing Consumption Value by Region (2020-2031)
8.3.2 China Solid Tumor Non-Conventional Testing Market Size and Forecast (2020-2031)
8.3.3 Japan Solid Tumor Non-Conventional Testing Market Size and Forecast (2020-2031)
8.3.4 South Korea Solid Tumor Non-Conventional Testing Market Size and Forecast (2020-2031)
8.3.5 India Solid Tumor Non-Conventional Testing Market Size and Forecast (2020-2031)
8.3.6 Southeast Asia Solid Tumor Non-Conventional Testing Market Size and Forecast (2020-2031)
8.3.7 Australia Solid Tumor Non-Conventional Testing Market Size and Forecast (2020-2031)
9 South America
9.1 South America Solid Tumor Non-Conventional Testing Consumption Value by Type (2020-2031)
9.2 South America Solid Tumor Non-Conventional Testing Consumption Value by Application (2020-2031)
9.3 South America Solid Tumor Non-Conventional Testing Market Size by Country
9.3.1 South America Solid Tumor Non-Conventional Testing Consumption Value by Country (2020-2031)
9.3.2 Brazil Solid Tumor Non-Conventional Testing Market Size and Forecast (2020-2031)
9.3.3 Argentina Solid Tumor Non-Conventional Testing Market Size and Forecast (2020-2031)
10 Middle East & Africa
10.1 Middle East & Africa Solid Tumor Non-Conventional Testing Consumption Value by Type (2020-2031)
10.2 Middle East & Africa Solid Tumor Non-Conventional Testing Consumption Value by Application (2020-2031)
10.3 Middle East & Africa Solid Tumor Non-Conventional Testing Market Size by Country
10.3.1 Middle East & Africa Solid Tumor Non-Conventional Testing Consumption Value by Country (2020-2031)
10.3.2 Turkey Solid Tumor Non-Conventional Testing Market Size and Forecast (2020-2031)
10.3.3 Saudi Arabia Solid Tumor Non-Conventional Testing Market Size and Forecast (2020-2031)
10.3.4 UAE Solid Tumor Non-Conventional Testing Market Size and Forecast (2020-2031)
11 Market Dynamics
11.1 Solid Tumor Non-Conventional Testing Market Drivers
11.2 Solid Tumor Non-Conventional Testing Market Restraints
11.3 Solid Tumor Non-Conventional Testing Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Solid Tumor Non-Conventional Testing Industry Chain
12.2 Solid Tumor Non-Conventional Testing Upstream Analysis
12.3 Solid Tumor Non-Conventional Testing Midstream Analysis
12.4 Solid Tumor Non-Conventional Testing Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Abbott Laboratories
Agilent Technologies
Avant Diagnostics, Inc.
Advanced Cell Diagnostics, Inc.
Agena Bioscience, Inc.
ARUP Laboratories
Bio-Rad Laboratories, Inc.
Biocare Medical, LLC.
Caris Life Sciences.
F. Hoffmann-La Roche Ltd
Foundation Medicine
Genomic Testing Cooperative
Guardant Health
HTG Molecular Diagnostics, Inc.
Illumina, Inc.
Invitae Corporation
Invivoscribe, Inc.
Johnson & Johnson
Laboratory Corporation of America Holdings
MedGenome Labs Private Ltd.
Myraid Genetics, Inc.
Nanjing Geneseeq
NanoString
NeoGenomics Laboratories
Opko Health, Inc.
QIAGEN
Quest Diagnostics Incorporated.
Thermo Fisher Scientific, Inc.
VYANTbio.
听
听
*If Applicable.
